HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

Friday, 2 December 2016

NICE approves three quarters of CDF group 1 drugs for routine use

From the NICE website:
“More than 75% of treatments in the Cancer Drugs Fund (CDF) which have been looked at again by NICE have received positive recommendations for routine NHS use.

It means that drugs, which patients previously had to apply to the CDF for, will now be available routinely on the NHS.  NICE is currently reappraising 11 drug indications in the first group of the CDF, and of the nine looked at so far, seven have been approved at draft or final guidance stage. None have yet been rejected in final guidance, with the remaining two currently in the process.”

Image: NICE by Sasha Cresdee